Anti-cancer Immunotoxins, Challenges, and Approaches

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Recombinant immunotoxins (RITs) are engineered proteins combining antibodies and toxins to target cancer cells.
• RITs function by inhibiting protein synthesis within cancerous cells, leading to cell death.
• Despite their efficacy against various cancers, RITs often trigger an immune response, limiting their clinical use.

Purpose of the Study:

• To review recent advancements in designing RITs with reduced immunogenicity.
• To explore strategies for overcoming immune system rejection of RITs.
• To highlight innovations in RIT development for improved cancer therapy.

Main Methods:

• Review of current literature on RIT development and immunogenicity.
• Analysis of strategies employed to mitigate immune responses to RITs.
• Examination of modifications to antibody and toxin components of RITs.

Main Results:

• Several strategies show promise in lowering RIT immunogenicity.
• Humanization of antibody fragments and modification of toxin moieties are effective approaches.
• Utilizing endogenous human cytotoxic enzymes can also reduce immune reactions.

Conclusions:

• Reducing RIT immunogenicity is crucial for successful clinical translation.
• Ongoing research focuses on engineering safer and more effective RITs.
• These advancements pave the way for broader application of RITs in cancer treatment.